How vets are using liquid bx- clinical performance

Approved for one hour California Statutory CEU

**Click Here to Register**

Objective: Once a test has been validated and is commercially available, it is important for the laboratory to periodically report utilization and performance metrics regarding the test. Blood-based liquid biopsy using next-generation sequencing became clinically available in May 2021. Since that time, the test has been ordered for thousands of patients, primarily as a screening tool for dogs at higher risk of cancer, and as an aid in diagnosis for dogs for which there is a clinical suspicion of cancer. This session will review data from a cohort of 1,500 consecutive liquid biopsy tests received for commercial testing at one clinical laboratory, and will include a discussion of ordering patterns, positivity rates, and patient outcome data, along with how this data can be used to discuss liquid biopsy testing with clients. A series of interesting case studies will be presented, exploring the use of this testing in a variety of clinical settings. 

Speaker Bio: Gina Brandstetter, DVM

Dr. Gina Brandstetter is a graduate of the UC Davis School of Veterinary Medicine. She has experience in small animal general practice and special interests in oncology, geriatric care, preventive care, and scientific communication. In her current position as a Medical Science Liaison at PetDx, Dr. Brandstetter is passionate about enhancing our approach to cancer detection and management with the adoption of liquid biopsy. Outside of work, she enjoys travel, spending time in nature, and going on family trips that include her yellow lab who loves nothing more than tagging along on any adventure.

Sponsor: